Pulmonary hypertension
Conditions
Interventions
PF patient group:None
PH patient group:None
Control group:None
Sponsors
Wuxi people’s Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.PH Patient Group: Patients must meet the international diagnostic criteria for PH, specifically confirmed by right heart catheterization with a mean pulmonary arterial pressure (mPAP) >=25 mmHg. According to the etiology, PH is divided into five main subtypes: primary pulmonary arterial hypertension, PH caused by left heart disease, PH caused by lung diseases, chronic thromboembolic PH, and PH associated with other diseases. During the diagnostic process, other potential causes of elevated pulmonary arterial pressure need to be excluded, and a comprehensive assessment should be made based on the patient's clinical symptoms, imaging examinations (such as chest X-ray, CT, etc.), and laboratory tests (such as blood gas analysis, BNP levels, etc.). Additionally, all patients must be between 18 and 75 years old, be able to understand the purpose and requirements of the study, and be capable of signing an informed consent form. Patients must voluntarily participate in this study and agree to provide valid clinical samples (such as blood, lung tissue, etc.) for subsequent biomarker screening, genomic analysis, and other related experimental studies. Patients must not be participating in other ongoing treatments that could affect the study, and the study should not negatively impact their current treatment. Participants are required to maintain regular check-ups and data submission during clinical follow-up to enable long-term observation of disease progression and treatment response. 2.PF Patient Group: PF patients must meet international diagnostic criteria and be diagnosed with pulmonary fibrosis, including patients with interstitial lung disease (ILD)-associated pulmonary hypertension. Diagnostic criteria include imaging examinations (such as high-resolution chest CT) showing typical manifestations of pulmonary fibrosis, combined with clinical symptoms and pulmonary function assessments, confirming evidence of pulmonary fibrosis. Patients must be between 18 and 75 years old and have the ability to understand the study content and participation requirements. All patients voluntarily participate in this study and sign informed consent forms to ensure they fully understand the purpose, methods, and potential risks of the study during the informed consent process. Patients must agree to provide valid clinical samples (such as blood, lung tissue, etc.) for subsequent biomarker screening, genomics analysis, proteomics research, and other related experiments. These samples will be used for in-depth analysis of potential biomarkers and therapeutic targets associated with pulmonary fibrosis and pulmonary hypertension. During the study, participants are required to undergo regular clinical evaluations and follow-ups to monitor disease progression and treatment response. 3.Control group: This study will recruit control group patients who are age- and gender-matched with the patient group, ensuring that they do not have any diseases related to the disease under investigation. All patients are those with pulmonary nodules admitted for surgical evaluation, capable of fully understanding the purpose and procedures of the study, and have signed informed consent forms, confirming their participation in the study on an informed basis. Blood samples are the surplus from routine blood draws during hospital admission evaluations, and lung tissue is the distal normal tissue from surgically resected diseased lungs, used for experiments such as biomarker screeni
Exclusion criteria
Exclusion criteria: 1.PH patient group: Exclusion criteria include patients with severe diabetes, liver or kidney dysfunction, or other systemic diseases. These conditions may affect the clinical manifestations and study outcomes of pulmonary hypertension (PH), thereby interfering with the accuracy of the data. Additionally, pregnant or breastfeeding women will be excluded to avoid potential risks to maternal and infant health during the study. Patients with a recent history of major surgery or serious infection are also not eligible for inclusion, as these factors may lead to unstable clinical conditions and affect the reliability of the study. Patients with malignant tumors, immune system disorders, or other diseases that may impact study results are likewise excluded. Finally, patients unable to provide sufficient biological samples (such as blood, lung tissue, etc.) for further analysis are also not eligible for inclusion. 2.PF Patient Group: The exclusion criteria for this group include patients with severe heart disease, diabetes, liver or kidney dysfunction, or other systemic diseases, as these conditions may be associated with pulmonary fibrosis and could affect the analysis of study results. Pregnant or breastfeeding women are also excluded to avoid any unnecessary risks associated with the study. Patients with a recent history of major surgery or severe infection will not be included, as these health conditions could cause rapid changes in clinical status and affect the stability of experimental data. Patients with malignant tumors, immune system diseases, or any other conditions that could impact the study results also do not meet the study criteria. Finally, patients who are unable to provide sufficient biological samples (such as blood or lung tissue) for further analysis will be excluded. 3.Control group: The exclusion criteria for this group include the presence of any diseases related to the condition being studied, as these diseases could affect the screening and analysis of biomarkers. Pregnant or breastfeeding women will be excluded to ensure that there are no potential risks to maternal or infant health in the study. Patients with a recent history of major surgery or severe infection are also not eligible for inclusion, as these factors may impact physiological status and the reliability of experimental results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary artery pressure;Pulmonary fibrosis; | — |
Countries
China
Contacts
Public ContactChen Yuan
Wuxi people’s Hospital
Outcome results
None listed